Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Рак молочной железы: от общих рекомендаций к персонализированной онкологии
Рак молочной железы: от общих рекомендаций к персонализированной онкологии
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В обзоре рассматриваются вопросы и возможности таргетной терапии рака молочной железы (РМЖ) на современном этапе в зависимости от биологического подтипа опухоли. Появление новых клинических данных по уже используемым в рутинной практике таргетным препаратам и их комбинациям, новых лекарственных средств из арсенала персонализированной медицины приводит к изменению терапевтических подходов. Большое внимание в обзоре уделено HER2-положительному подтипу РМЖ. Приводятся данные по клиническим исследованиям лекарственных препаратов пертузумаба и Т-DМ1, которые могут изменить стандарты терапии HER2-положительного РМЖ. В обзоре также рассматриваются предиктивное значение индекса рецидивирования при люминальном подтипе и биологические особенности тройного негативного РМЖ.
Ключевые слова: трастузумаб, трастузумаб для подкожного введения, пертузумаб, T-DM1.
Key words: trastuzumab, subcutaneous trastuzumab, pertuzumab, T-DM1.
Ключевые слова: трастузумаб, трастузумаб для подкожного введения, пертузумаб, T-DM1.
________________________________________________
Key words: trastuzumab, subcutaneous trastuzumab, pertuzumab, T-DM1.
Полный текст
Список литературы
1. Goldhirsch A. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 2011; 22 (8): 1736–47.
2. Paik S et al. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. NEJM 2004; 351 (27): 2817.
3. Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24 (23): 3726–34.
4. NCCN guidelines. Version 2; 2011.
5. Ismael G et al. Subcutaneous versus intravenous administration of (neo) adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012; 13 (9): 869–78.
6. Gianni L et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13 (1): 25–32.
7. Baselga J et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012.
8. Guarneri V et al. Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study. JCO 2012.
9. Robidoux A et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. ASCO 2012; LBA 506.
10. Baselga J et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med 2012; 366: 109–9.
11. Swain S et al. Confirmatory overall survival (OS) analysis of CLEOPATRA: A randomized, double blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC). Cancer Res 2012; 72 (Suppl. 24).
12. Hurvitz SA et al. Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450 g/BO21976). ESMO 2011; Abstr 5001.
13. Gluz O et al. Triple-negative breast cancer – current status and future directions. Ann Oncol 2009; 20: 1913–27.
14. Lehmann BD et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Inv 2011; 12 (7): 2750–67.
15. Gelmon K et al. Targeting triple-negative breast cancer: optimizing therapeutic outcomes. Ann Oncol 2012; 23 (9): 2223–34.
16. Romond EH et al. Seven-year follow-up assessment of cardiac function in nsabp b-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (acp) with acp plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30: 3792–9.
17. Curtis C et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012; 486: 346–52.
18. Blackwell K et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. ASCO 2012; LBA1.
19. Verma S et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med 2012; 367: 1783–91.
2. Paik S et al. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. NEJM 2004; 351 (27): 2817.
3. Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24 (23): 3726–34.
4. NCCN guidelines. Version 2; 2011.
5. Ismael G et al. Subcutaneous versus intravenous administration of (neo) adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012; 13 (9): 869–78.
6. Gianni L et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13 (1): 25–32.
7. Baselga J et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012.
8. Guarneri V et al. Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study. JCO 2012.
9. Robidoux A et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. ASCO 2012; LBA 506.
10. Baselga J et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med 2012; 366: 109–9.
11. Swain S et al. Confirmatory overall survival (OS) analysis of CLEOPATRA: A randomized, double blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC). Cancer Res 2012; 72 (Suppl. 24).
12. Hurvitz SA et al. Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450 g/BO21976). ESMO 2011; Abstr 5001.
13. Gluz O et al. Triple-negative breast cancer – current status and future directions. Ann Oncol 2009; 20: 1913–27.
14. Lehmann BD et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Inv 2011; 12 (7): 2750–67.
15. Gelmon K et al. Targeting triple-negative breast cancer: optimizing therapeutic outcomes. Ann Oncol 2012; 23 (9): 2223–34.
16. Romond EH et al. Seven-year follow-up assessment of cardiac function in nsabp b-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (acp) with acp plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30: 3792–9.
17. Curtis C et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012; 486: 346–52.
18. Blackwell K et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. ASCO 2012; LBA1.
19. Verma S et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med 2012; 367: 1783–91.
Авторы
ПьерФранко Конте, Валентина Гварнери
Университетская клиника г. Падуя, Италия
Университетская клиника г. Падуя, Италия
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.